Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs

Executive Summary

J&J’s Janssen Biotech subsidiary won FDA approval for the IL-12/IL-23 inhibitor Stelara to treat Crohn’s disease, giving it a second-line position alongside anti-TNF therapies for patients in need of new options.

Advertisement

Related Content

Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
Indication-Based Pricing Could Be Windfall For Interleukin Inhibitors
Express Scripts Indication-Based Contracts For Inflammatory Drugs Begin In 2017
Evolving Takeda Signals Intent To Build Around Entyvio, GI Franchise
TiGenix The Latest Partner In Takeda Deal Frenzy
Crohn's Pipeline: Janssen Seeks New Niche For Stelara As Biologics Use Rises
Celgene Diversifying Beyond Myeloma Backbone Revlimid
INFOGRAPHIC: RA pipeline has limited new options

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097368

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel